The acquisition of secondary mutations in the tyrosine kinase domain (TKD) of FLT3 is one mechanism of such resistance (6, 10), and has been identified in AML patients who relapsed or developed resistance to type-2 FLT3is, such as sorafenib and quizartinib (6, 11). Here, FLT3 is linked to acute myeloid leukemia.